IBA Delivers Europe’s First Proteus®ONE Proton Therapy Solution to Centre Antoine Lacassagne, Nice, France

IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has shipped and delivered Proteus®ONE*’s unique compact superconducting proton therapy accelerator to the Centre Antoine Lacassagne in Nice, France.

Louvain-la-Neuve, Belgium, April 10th, 2014 -  Centre Antoine Lacassagne will be the first proton therapy centre in Europe to have this compact proton therapy system. The site is expected to be operational by the end of 2015.

Proteus®ONE has been developed by IBA to allow more patients to access proton therapy globally. Proteus®ONE makes proton therapy easily accessible to clinical institutions. It is a smaller, less expensive and faster to install proton therapy solution, encompassing the latest in precision technology, including Intensity Modulated Proton Therapy (IMPT). IBA has already sold three Proteus®ONE systems worldwide: in Shreveport (USA), Nice (France) and Taiwan (Asia).

From a technology standpoint, the shipping of this first superconducting accelerator is another major milestone in the development of Proteus®ONE. IBA has also submitted all necessary documentation on its first compact proton therapy gantry to the U.S. Food and Drug Administration (FDA) and IBA expects to receive Marketing Authorization for Proteus®ONE later this year.

Olivier Legrain, Chief Executive Officer of IBA, commented: “We are delighted to begin onsite installation of this revolutionary proton therapy solution. Making proton therapy smaller and more affordable is a key strategic goal of IBA and the Proteus®ONE system delivers exactly that. We are confident this is the first installation of many as we are seeing a growing international interest in proton therapy, in particular the Proteus®ONE solution, owing to the fact it is smaller and cheaper, breaking down barriers to entry.”

About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its
superior dose distribution and reduced side effects. Protons deposit the majority of their
effective energy within a precisely controlled range within a tumor, sparing healthy
surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of
side effects and long-term complications, improving patient outcomes and quality of life.
Today, more than half of proton therapy clinical facilities worldwide utilize IBA systems. This
includes 17 proton therapy centers in operation and 9 centers under development. Over 25
000 patients have been treated on IBA equipment – more than all competitor installations

About Proteus®ONE*

Proteus®ONE is the compact IMPT** solution from IBA. It benefits from the latest
technologies of Proteus®PLUS, developed with top clinical institutions. Proteus®ONE is
smaller, more affordable, easier to install, easier to operate and ultimately easier to finance,
making this advanced radiotherapy modality available to more institutions worldwide.
Proteus®ONE makes Proton Therapy accessible to more patients worldwide.

*Proteus®ONE is the brand name of a new configuration of the Proteus® 235, including some new
developments subject to review by Competent Authorities (FDA, European Notified Bodies, et al.) before
** Intensity Modulated Proton Therapy

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company,
and the worldwide technology leader in the field of proton therapy, the most advanced form of
radiotherapy available today.

The Company’s primary expertise lies in the development of next generation proton therapy
technologies that provide oncology care providers with premium quality services and
equipment. IBA’s proton therapy solutions are scalable and adaptable, offering universal full
scale proton therapy centers as well as next generation compact, single room systems. IBA
also focuses on the development and supply of dosimetry solutions for Quality Assurance of
medical equipment and increased patient safety as well as particle accelerators for medical
and industrial applications.

Headquartered in Belgium and employing more than 1,000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com